Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer

  Free Subscription


03.07.2017

1 APMIS
1 Asian Pac J Trop Med
2 BJU Int
2 Can J Urol
2 Can Urol Assoc J
2 Cancer
1 Clin Genitourin Cancer
1 Curr Opin Urol
1 Diabetes Obes Metab
1 Dis Markers
1 Eur Urol
1 Future Oncol
1 Harefuah
1 In Vivo
1 J Clin Diagn Res
1 J Clin Invest
1 J Urol
1 Lab Invest
1 Mol Cancer Ther
1 Mol Med Rep
1 Oncology
1 Oncotarget
1 Sci Rep
2 Urol Oncol
1 Urologe A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    APMIS

  1. CAKIR E, Kucuk U, Pala EE, Sezer O, et al
    Cytopathologic differential diagnosis of low-grade urothelial carcinoma and reactive urothelial proliferation in bladder washings: a logistic regression analysis.
    APMIS. 2017;125:431-436.
    PubMed     Text format     Abstract available


    Asian Pac J Trop Med

  2. YANG Y, Guo JX, Shao ZQ, Gao JP, et al
    Matrine inhibits bladder cancer cell growth and invasion in vitro through PI3K/AKT signaling pathway: An experimental study.
    Asian Pac J Trop Med. 2017;10:515-519.
    PubMed     Text format     Abstract available


    BJU Int

  3. MCCOMBIE SP, Bangash HK, Kuan M, Thyer I, et al
    Delays in the diagnosis and initial treatment of bladder cancer in Western Australia.
    BJU Int. 2017 Jun 29. doi: 10.1111/bju.13939.
    PubMed     Text format     Abstract available

  4. SOAVE A, Riethdorf S, Dahlem R, Minner S, et al
    Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
    BJU Int. 2017;119:854-861.
    PubMed     Text format     Abstract available


    Can J Urol

  5. MORALES A
    BCG: A throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy.
    Can J Urol. 2017;24:8788-8793.
    PubMed     Text format     Abstract available

  6. FITZPATRICK R, Paterson NR, Belanger EC, McCurdy A, et al
    Primary amyloidosis of the bladder; a mimicker of bladder cancer.
    Can J Urol. 2017;24:8868-8870.
    PubMed     Text format     Abstract available


    Can Urol Assoc J

  7. TRABOULSI SL, Brimo F, Yang Y, Maedler C, et al
    Pathology review impacts clinical management of patients with T1-T2 bladder cancer.
    Can Urol Assoc J. 2017;11:188-193.
    PubMed     Text format     Abstract available

  8. KLAASSEN Z, Li K, Kassouf W, Black PC, et al
    Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
    Can Urol Assoc J. 2017;11:173-181.
    PubMed     Text format     Abstract available


    Cancer

  9. DOLAN RD, McMillan DC
    Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30872.
    PubMed     Text format    

  10. OJERHOLM E, Smith A, Hwang WT, Christodouleas JP, et al
    Reply to Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30871.
    PubMed     Text format    


    Clin Genitourin Cancer

  11. LI C, Cui Y, Liu LF, Ren WB, et al
    High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.
    Clin Genitourin Cancer. 2017 May 10. pii: S1558-7673(17)30125.
    PubMed     Text format     Abstract available


    Curr Opin Urol

  12. GILD P, Ehdaie B, Kluth LA
    Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival.
    Curr Opin Urol. 2017 Jun 24. doi: 10.1097/MOU.0000000000000425.
    PubMed     Text format     Abstract available


    Diabetes Obes Metab

  13. GARRY EM, Buse JB, Lund JL, Pate V, et al
    Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives on the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jun 29. doi: 10.1111/dom.13049.
    PubMed     Text format     Abstract available


    Dis Markers

  14. MENG XY, Shi MJ, Chen JF, Liao Y, et al
    Association between the TACC3 rs798766 Polymorphism and Risk of Urinary Bladder Cancer: A Synthesis Based on Current Evidence.
    Dis Markers. 2017;2017:7850708.
    PubMed     Text format     Abstract available


    Eur Urol

  15. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    PubMed     Text format    


    Future Oncol

  16. ATTALLA K, Kent M, Waingankar N, Mehrazin R, et al
    Robotic-assisted radical cystectomy versus open radical cystectomy for management of bladder cancer: review of literature and randomized trials.
    Future Oncol. 2017;13:1195-1204.
    PubMed     Text format     Abstract available


    Harefuah

  17. NOROHEIMER S, Ozalvo R, Abramovich A, Fenig E, et al
    [THE MULTIDISCIPLINARY MUSCLE INVASIVE BLADDER CANCER CLINIC AT THE RABIN MEDICAL CENTER].
    Harefuah. 2017;:349-352.
    PubMed     Text format    


    In Vivo

  18. MANIG L, Janssen S, Schild SE, Rades D, et al
    A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer.
    In Vivo. 2017;31:745-748.
    PubMed     Text format     Abstract available


    J Clin Diagn Res

  19. SOMASEKAR R, Naganathbabu O, Prabhakaran R, Gnanasekar M, et al
    Salvage Surgery for Metastatic Gall Bladder Cancer with Vanishing Liver Metastasis Following Palliative 5-Fluorouracil Metronomic Chemotherapy.
    J Clin Diagn Res. 2017;11:XD03-XD05.
    PubMed     Text format     Abstract available


    J Clin Invest

  20. CHEVALIER MF, Trabanelli S, Racle J, Salome B, et al
    ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
    J Clin Invest. 2017 Jun 26. pii: 89717. doi: 10.1172/JCI89717.
    PubMed     Text format     Abstract available


    J Urol

  21. ARK JT, Alvarez JR, Koyama T, Bassett JC, et al
    Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race, and risk factors for bladder cancer.
    J Urol. 2017 Jun 24. pii: S0022-5347(17)76746-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    Lab Invest

  22. ESKAROS AR, Egloff SA, Boyd KL, Richardson JE, et al
    Larger core size has superior technical and analytical accuracy in bladder tissue microarray.
    Lab Invest. 2017;97:335-342.
    PubMed     Text format     Abstract available


    Mol Cancer Ther

  23. ZIMMERMANN M, Wang SS, Zhang H, Lin TY, et al
    Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
    Mol Cancer Ther. 2017;16:376-387.
    PubMed     Text format     Abstract available


    Mol Med Rep

  24. WEI Z, Hu X, Liu J, Zhu W, et al
    MicroRNA-497 upregulation inhibits cell invasion and metastasis in T24 and BIU-87 bladder cancer cells.
    Mol Med Rep. 2017 Jun 19. doi: 10.3892/mmr.2017.6805.
    PubMed     Text format     Abstract available


    Oncology

  25. MIYAKE M, Morizawa Y, Hori S, Marugami N, et al
    Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
    Oncology. 2017 Jun 24. doi: 10.1159/000477405.
    PubMed     Text format     Abstract available


    Oncotarget

  26. WHANG YM, Jin SB, Park SI, Chang IH, et al
    MEK inhibition enhances efficacy of bacillus Calmette-Guerin on bladder cancer cells by reducing release of toll-like receptor 2-activated antimicrobial peptides.
    Oncotarget. 2017 May 26. doi: 10.18632/oncotarget.18230.
    PubMed     Text format     Abstract available


    Sci Rep

  27. WANG SC, Sung WW, Kao YL, Hsieh TY, et al
    The gender difference and mortality-to-incidence ratio relate to health care disparities in bladder cancer: National estimates from 33 countries.
    Sci Rep. 2017;7:4360.
    PubMed     Text format     Abstract available


    Urol Oncol

  28. WILLIAMS SB, Huo J, Dafashy TJ, Ghaffary CK, et al
    Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment.
    Urol Oncol. 2017 Jun 21. pii: S1078-1439(17)30252.
    PubMed     Text format     Abstract available

  29. APFELBECK M, Grimm T, Kretschmer A, Buchner A, et al
    Follow-up of high-risk bladder cancer-Is it safe to perform fluorescence endoscopy multiple times in the same patient?
    Urol Oncol. 2017 Jun 27. pii: S1078-1439(17)30262.
    PubMed     Text format     Abstract available


    Urologe A

  30. KUNATH F
    [Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer : Comment on a recently published Cochrane Review].
    Urologe A. 2017 Jun 26. doi: 10.1007/s00120-017-0436.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: